•
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and dosing in a Phase III clinical study for its NR082 (rAAV2-ND4, NFS-01), a recombinant adeno-associated virus serotype 2 (rAAV2) therapy for ND4-mediated Leber’s hereditary optic neuropathy (ND4-LHON). This marks a significant milestone in the development…
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that the market approval filing for its in-licensed Uro-G disposable hand-held electronic bladder endoscope catheter has been accepted for review by the National Medical Products Administration (NMPA). The company’s matching Uro-3500 electronic endoscope image processor is…
•
Merck KGaA (ETR: MRK), a leading German pharmaceutical company, has struck a partnership with the Beijing Municipal Medical Insurance Bureau. This collaboration will enable Merck to import a range of essential medications through Beijing ports, starting from 2023. The drugs include Concor (bisoprolol), Bisoprolol, Amlodipine, Glucophage XR (Metformin), and Stilamin…
•
China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19 drug designed with the support of the firm’s Chemistry42 platform, has entered clinical trials after receiving approval from the National Medical Products Administration (NMPA). This marks a significant milestone in the development of innovative treatments…
•
Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), a specialist in Chinese medical consumables, has announced a strategic partnership with the Qionghai municipal government and the Boao Lecheng Medical Tourism Pilot Zone of Hainan Province. The company plans to establish a science and technology park and an international medical research…
•
Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has announced a deepened strategic partnership with Levinthal Biotech, an AI-empowered protein design company headquartered in Hangzhou. The collaboration aims to advance research and development in next-generation gene therapy and mRNA vaccine fields, marking a significant step forward…
•
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase III TORCHLIGHT study for its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab). The study, which combines Tuoyi with paclitaxel and albumin, has completed its pre-set interim analysis for initially-diagnosed stage IV or recurrent metastatic triple-negative breast…
•
US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical Device Co., Ltd. The collaboration aims to leverage the respective strengths of both companies in technology, service network, and other areas to enhance the distribution of advanced medical technologies and solutions in China. Partnership Scope…
•
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted a filing for another indication approval for its potassium-competitive acid blocker (P-CAB), tegoprazan. The drug is being reviewed for the treatment of duodenal ulcers, expanding…
•
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products Administration (NMPA) has accepted a market approval filing for its Category 1 gastric acid blocker, X842. The targeted indication for this innovative drug is reflux esophagitis (RE), a condition affecting a significant number of patients…
•
We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly secured “tens of millions” of renminbi in an angel financing round. The funding round was led by Bluerun Ventures and CDH Investments, with participation from Naton Technology and Guokr.com. Company Background and AchievementsFounded in 2019,…
•
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot firm China Resource Medicine Commercial Holdings Ltd. The partnership aims to expand market reach, enhance promotion efforts, and boost sales. Financial details of the agreement were not disclosed. Hybio Pharma’s Strategic LeverageHybio Pharma, a key…
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission of a market approval filing for its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), to the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK. The company is seeking approval for the checkpoint inhibitor in…
•
Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the enrollment and dosing of the first subject in a Phase I/II clinical study for its ophthalmology gene therapy ZVS101e in Tianjin. This study marks the first potentially regulatory clinical trial for a gene therapy targeting…
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical study for its oral double prodrug ASC10. The findings were presented at the CROI 2023 annual meeting, marking a significant step forward in the development of this promising therapeutic candidate. Phase I Clinical Data HighlightsThe…
•
China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly secured an undisclosed amount of angel funding. The round was led by Tus Star, with participation from Wuxi Kelin Venture Capital Partnership. The proceeds will be directed towards accelerating the research and development of pelvic…
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a significant milestone. The company’s generic version of AbbVie’s (NYSE: ABBV) bimatoprost and timolol maleate eye drops has been granted approval in China. This approval is for use in lowering the intraocular pressure of patients…
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug limaprost. This therapeutic drug targets analgesia and microcirculation, addressing a significant health issue among the country’s population. Lumbar Spinal Stenosis: A Prevalent ConditionTubular stenosis, particularly lumbar spinal…
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,” an ambitious initiative designed to develop fully human nanobody drugs for over 100 targets. This project leverages Biocytogen’s proprietary fully human nanobody mouse, RenNano, in conjunction with its high-throughput in vitro and in vivo antibody…